Retatrutide, a innovative dual-acting glucose-dependent incretin analog, represents a significant progression in peptide therapeutics for the management of type 2 diabetic conditions and, increasingly, obesity. Unlike many existing medicinal interventions, retatrutide combines the actions of a GLP-1 receptor stimulant and a GIP receptor stimulant,